CA 327
Alternative Names: AUPM-327; CA-327; PD-L1/TIM-3 antagonists - Aurigene Oncology/CurisLatest Information Update: 28 Mar 2024
Price :
$50 *
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology; Curis
- Class Antineoplastics; Small molecules
- Mechanism of Action HAVCR2 protein inhibitors; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in India (PO)
- 31 Dec 2023 Curis files foreign patent application for PD-L1/TIM3 programme before December 2023
- 31 Dec 2023 Curis in-licenses IP rights from Aurigene for PD-L1/TIM3 programme in the US before December 2023